Scarica l'app Stockscreener
3.78
0.53%
-0.02
Dopo l'orario di chiusura:
3.78
Precedente Chiudi:
$3.80
Aprire:
$3.7
Volume 24 ore:
1.36M
Relative Volume:
1.76
Capitalizzazione di mercato:
$480.23M
Reddito:
$81.36M
Utile/perdita netta:
$-142.62M
Rapporto P/E:
-3.1476
EPS:
-1.2009
Flusso di cassa netto:
$-146.97M
1 W Prestazione:
-4.55%
1M Prestazione:
-9.57%
6M Prestazione:
-5.03%
1 anno Prestazione:
+184.21%
Intervallo 1D:
$3.60
$3.97
Intervallo di 1 settimana:
$3.56
$4.00
Portata 52W:
$1.05
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Nome
Adc Therapeutics Sa
Settore
Industria
Telefono
41 21 653 02 00
Indirizzo
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.78 | 480.23M | 81.36M | -142.62M | -146.97M | -1.2009 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-08 | Iniziato | Stephens | Overweight |
| 2024-05-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Iniziato | Guggenheim | Buy |
| 2023-08-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Iniziato | CapitalOne | Overweight |
| 2022-11-09 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-08-17 | Ripresa | Jefferies | Buy |
| 2021-08-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Iniziato | Stifel | Hold |
| 2020-10-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-06-09 | Iniziato | BofA/Merrill | Buy |
| 2020-06-09 | Iniziato | Cowen | Outperform |
Mostra tutto
Adc Therapeutics Sa Borsa (ADCT) Ultime notizie
Risk Off: Does ADC Therapeutics SA have a sustainable dividendWeekly Profit Analysis & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Insider Sell: What is the implied volatility of ADC Therapeutics SA2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
ADCT.N Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
ADCT Should I Buy - Intellectia AI
Next Generation Drug Conjugates (NDCs) Market Worth $42.55 Billion by 2035 | MarketsandMarkets - 富途牛牛
ADC Therapeutics delivers 70% return as Fair Value target hit - Investing.com
Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells $8,641,179.68 in Stock - MarketBeat
Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells 196,229 Shares of Stock - MarketBeat
Insider Selling: ADC Therapeutics (NYSE:ADCT) Major Shareholder Sells 169,265 Shares of Stock - MarketBeat
Redmile-managed funds trim ADC Therapeutics (ADCT) stake with 5.9M-share sale - Stock Titan
ADCT.N Technical Analysis & Stock Price Forecast - intellectia.ai
ADC Therapeutics Announces New Employee Inducement Grant - PR Newswire
Energy Moves: Is ADC Therapeutics SA in a consolidation phase2026 Retail Activity & Real-Time Volume Spike Alerts - baoquankhu1.vn
ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance - MSN
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update - Quantisnow
Nasdaq Moves: Is ADC Therapeutics SA a stock for growth or value investors2026 Setups & High Accuracy Buy Signal Tips - baoquankhu1.vn
ADC Therapeutics Eyes ZYNLONTA Expansion as LOTIS-5 Data Nears at H.C. Wainwright Chat - MarketBeat
ADC Therapeutics (NYSE:ADCT) Shares Gap Up on Analyst Upgrade - Defense World
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $8.00 - MarketBeat
ADC Therapeutics (ADCT) Reports 2025 Revenue of $73.6M With Cash Runway Into 2028 - Yahoo Finance
US Stocks Recap: Can ADC Therapeutics SA disrupt its industryRate Hike & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Heights Capital Management Inc. Has $1.31 Million Position in ADC Therapeutics SA $ADCT - MarketBeat
Growth Recap: Will ADC Therapeutics SA benefit from rate cuts2026 Dividend Review & Technical Entry and Exit Tips - baoquankhu1.vn
Fed Watch: Is ADC Therapeutics SA stock showing strong momentumMarket Rally & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
[EFFECT] ADC Therapeutics SA SEC Filing - Stock Titan
ADC Therapeutics (ADCT) registers 9.83M shares issuable on HCR warrants - Stock Titan
ADC Therapeutics signals ZYNLONTA peak revenue potential of $600M–$1B in U.S. with expanded clinical milestones - MSN
ADC Therapeutics SA $ADCT Stock Holdings Reduced by Prosight Management LP - MarketBeat
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Wall Street Recap: Can ADC Therapeutics SA expand its profit margins2026 Setups & Growth Focused Investment Plans - baoquankhu1.vn
ADC Therapeutics (NYSE:ADCT) Shares Down 9.2%Should You Sell? - MarketBeat
ADC Therapeutics SA Hits New 52-Week High of $4.95, Up 31.87% - Markets Mojo
ADC Therapeutics SA: 2025 Annual Report Highlights – ZYNLONTA Pipeline, Global Partnerships, and Antibody-Drug Conjugate Innovation - Minichart
ADC Therapeutics SA (ADCT) Reports Wider Loss Q4 EPS Estimates by 85.1% - AlphaStreet
ADC Therapeutics SA 2025 Q4ResultsEarnings Call Presentation (NYSE:ADCT) 2026-03-11 - Seeking Alpha
Aug Shorts: Can ADC Therapeutics SA continue delivering strong returns2026 PreEarnings & Weekly Stock Breakout Alerts - baoquankhu1.vn
ADC Therapeutics reports Q4 revenue of $22.3 million By Investing.com - Investing.com Canada
ADC Therapeutics (NYSE:ADCT) Reaches New 12-Month High Following Strong Earnings - MarketBeat
According to the latest filings submitted to the U.S. Securities and Exchange Commission (SEC), some shareholders of the biopharmaceutical company ADC Therapeutics SA may gradually sell their holdings of the company's common stock over a period of tim - Bitget
ADC Therapeutics 2025 10-K: $81.4M Revenue, $(1.12) EPS - TradingView
[ARS] ADC Therapeutics SA SEC Filing - Stock Titan
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
ADC Therapeutics Q4 2025 Earnings Call Insights - Intellectia AI
ADC Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
ADC Therapeutics SA Files 8-K Report Detailing Company Information and Common Shares Listing on NYSE - Minichart
ADC Therapeutics Q4 Earnings Call Highlights - MarketBeat
ADC Therapeutics (NYSE:ADCT) Shares Gap Up After Strong Earnings - MarketBeat
ADC Therapeutics Narrows Losses, Supported By Higher Product Revenue And Ongoing Restructuring - RTTNews
ADC Therapeutics reports Q4 revenue of $22.3 million - Investing.com
ADC Therapeutics SA reports results for the quarter ended December 31Earnings Summary - TradingView
Adc Therapeutics Sa Azioni (ADCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):